Verve Therapeutics Inc (NASDAQ: VERV) on Tuesday, soared 1.37% from the previous trading day, before settling in for the closing price of $10.93. Within the past 52 weeks, VERV’s price has moved between $2.86 and $11.40.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -42.43% over the past five years. The company achieved an average annual earnings per share of -4.53%. With a float of $65.76 million, this company’s outstanding shares have now reached $88.80 million.
Let’s look at the performance matrix of the company that is accounted for 274 employees. In terms of profitability, gross margin is 36.09%, operating margin of -349.68%, and the pretax margin is -303.09%.
Verve Therapeutics Inc (VERV) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Verve Therapeutics Inc is 26.23%, while institutional ownership is 73.90%. The most recent insider transaction that took place on Apr 02 ’25, was worth 40,761. In this transaction Chief Executive Officer of this company sold 9,822 shares at a rate of $4.15, taking the stock ownership to the 346,686 shares. Before that another transaction happened on Apr 02 ’25, when Company’s Chief Administrative Officer sold 2,777 for $4.15, making the entire transaction worth $11,525. This insider now owns 17,420 shares in total.
Verve Therapeutics Inc (VERV) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -4.53% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -0.31% during the next five years compared to -42.43% drop over the previous five years of trading.
Verve Therapeutics Inc (NASDAQ: VERV) Trading Performance Indicators
Verve Therapeutics Inc (VERV) is currently performing well based on its current performance indicators. A quick ratio of 9.84 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 16.57.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.11, a number that is poised to hit -0.69 in the next quarter and is forecasted to reach -2.82 in one year’s time.
Technical Analysis of Verve Therapeutics Inc (VERV)
Verve Therapeutics Inc (NASDAQ: VERV) saw its 5-day average volume 3.78 million, a positive change from its year-to-date volume of 3.43 million. As of the previous 9 days, the stock’s Stochastic %D was 29.19%.
During the past 100 days, Verve Therapeutics Inc’s (VERV) raw stochastic average was set at 96.25%, which indicates a significant increase from 40.91% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.11 in the past 14 days, which was lower than the 0.41 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.94, while its 200-day Moving Average is $6.39. Nevertheless, the first resistance level for the watch stands at $11.14 in the near term. At $11.21, the stock is likely to face the second major resistance level. The third major resistance level sits at $11.32. If the price goes on to break the first support level at $10.96, it is likely to go to the next support level at $10.85. Assuming the price breaks the second support level, the third support level stands at $10.78.
Verve Therapeutics Inc (NASDAQ: VERV) Key Stats
Market capitalization of the company is 987.71 million based on 89,143K outstanding shares. Right now, sales total 32,330 K and income totals -198,710 K. The company made 32,980 K in profit during its latest quarter, and -31,030 K in sales during its previous quarter.
